Related Experiment Video
Updated: Jan 1, 2026
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach
Taku Tsukamoto1, Shingo Nakahata2, Ryuichi Sato3
1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Background:
Since bromodomain-containing protein 4 (BRD4) facilitates the transcription of genes important for neoplastic cells in a cancer-type specific manner, BRD4-regulated molecules may also include therapeutic targets for mantle cell lymphoma (MCL), a treatment-refractory subtype of malignant lymphoma.
Materials And Methods:
In order to uncover direct BRD4-regulated targets in MCL, we performed integrated analysis using the pathway database and the results of both gene-expression profiling and chromatin immunoprecipitation with parallel sequencing for BRD4.
Results:
Treatment with BRD4 inhibitor I-BET151 exerted a dose-dependent inhibitory effect on cell proliferation in MCL cell lines. BRD4 was found to directly regulate series of genes involved in the B-cell receptor (BCR) signaling pathway, including B-cell linker (BLNK), paired box 5 (PAX5), and IKAROS family zinc finger 3 (IKZF3), and several oncogenes, such as MYB. Indeed, the combinatory inhibition of BCR pathway and IKZF showed an additive antitumor effect.
Conclusion:
Concomitant targeting multiple BRD4-regulated molecules may constitute a rational therapeutic strategy for MCL.
Insights
Targeting bromodomain-containing protein 4 (BRD4) and its downstream molecules, including those in the B-cell receptor (BCR) pathway, shows promise for treating mantle cell lymphoma (MCL). This approach may offer a new therapeutic strategy for this difficult-to-treat cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Bromodomain-containing protein 4 (BRD4) is crucial for transcribing genes in neoplastic cells.
- Mantle cell lymphoma (MCL) is a treatment-refractory cancer where BRD4-regulated molecules are potential therapeutic targets.
Purpose of the Study:
- To identify direct BRD4-regulated target genes in mantle cell lymphoma.
- To explore the therapeutic potential of targeting BRD4 in MCL.
Main Methods:
- Integrated analysis of pathway databases, gene-expression profiling, and BRD4 chromatin immunoprecipitation with sequencing.
- Treatment of MCL cell lines with BRD4 inhibitor I-BET151.
Main Results:
- BRD4 inhibition with I-BET151 reduced MCL cell proliferation in a dose-dependent manner.
- BRD4 directly regulates genes in the B-cell receptor (BCR) signaling pathway (e.g., BLNK, PAX5, IKZF3) and oncogenes (e.g., MYB).
- Combined inhibition of BCR pathway and IKZF3 demonstrated an additive antitumor effect.
Conclusions:
- Targeting multiple BRD4-regulated molecules simultaneously is a rational therapeutic strategy for MCL.
- This approach offers a promising avenue for overcoming treatment resistance in mantle cell lymphoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...